-
Options Brief: MannKind
Friday, August 12, 2011 - 11:03am | 73Shares of MannKind (NASDAQ: MNKD) are higher on the session by 20.67%, trading at $2.86. Overall call volume is now running at 2.94x the daily average, with 51% of all calls traded being purchases on the offer. 5,507 contracts have traded on the session so far. MannKind Corporation is a...
-
UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50
Friday, August 12, 2011 - 9:10am | 41MLV reiterated its Buy rating on Novavax (NASDAQ: NVAX). At the same time, the rating agency reduced its price target on the company's stock from $11 to $9.50. On Thursday, NVAX closed the day at $1.33.
-
Rodman & Renshaw Reiterates Market Outperform and PT of $10 on SciClone Pharmaceuticals
Friday, August 12, 2011 - 9:04am | 44Rodman & Renshaw reiterated its Market Outperform rating on SciClone Pharmaceuticals (NASDAQ: SCLN). At the same time, the rating agency left its price target on the company's stock unchanged at $10. On Thursday, SCLN closed the day at $5.07.
-
Global Hunter Initiates Aastrom Biosciences At Speculative Buy, $6 PT
Friday, August 12, 2011 - 8:29am | 27Global Hunter Securities has initiated coverage on Aastrom Biosciences (NASDAQ: ASTM) with a Speculative Buy rating and $6 price target.
-
Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Friday, August 12, 2011 - 8:00am | 177Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Robert E. Hoffman will rejoin Arena on August 29, 2011, as Vice President, Finance and Chief Financial Officer. Mr. Hoffman served in various financial positions with Arena for over 13 years before departing in March to work for a...
-
News Summary for August 12, 2011
Friday, August 12, 2011 - 7:50am | 554This is your Benzinga news summary and traders' outlook for Friday, August 12, 2011, covering headlines from overnight and Friday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading flat after a 400 point rally in the Dow yesterday. At last check, Dow...
-
Citi Reiterates Buy and PT of $200 on Pharmasset
Friday, August 12, 2011 - 7:10am | 46Citi reiterated its Buy rating on Pharmasset (NASDAQ: VRUS). At the same time, the rating agency left its price target on the company's stock unchanged at $200. On Thursday, VRUS added 4.73% to its value to finish the day at $116.85.
-
Earnings Scheduled For August 12
Friday, August 12, 2011 - 3:22am | 135J.C. Penney Company Inc (NYSE: JCP) is projected to report its Q2 EPS at $0.06 on revenue of $3.91 billion. China TransInfo Technology Corp (NASDAQ: CTFO) is expected to report its Q2 EPS at $0.10 on revenue of $32.48 million. Conmed Healthcare Management Inc (AMEX: CONM) is estimated to report...
-
MannKind Confirms Design of Pivotal Studies
Thursday, August 11, 2011 - 10:22pm | 151MannKind (NASDAQ: MNKD) today announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of AFREZZA, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-...
-
Rodman & Renshaw Reiterates Outperform Rating on Oncothyreon
Thursday, August 11, 2011 - 5:08pm | 133Rodman & Renshaw is out with a research report this afternoon, where it reiterates its Outperform rating on Oncothyreon (NASDAQ: ONTY); it has a $10.00 price target on the stock. The R&R analysts cited the company's recent earnings results, which ere worse than expected as a result of an...
-
Rodman & Renshaw Reiterates Oncothyreon Market Outperform, $10 PT
Thursday, August 11, 2011 - 4:45pm | 80Rodman & Renshaw reiterated its Oncothyreon (NASDAQ: ONTY) Market Outperform rating and $10 price target in a research report published today. In the report, Rodman & Renshaw states, "We believe that the promising Phase 2 data for Stimuvax establishes the potential for success in two...
-
McNicoll, Lewis & Vlak Reiterates Affymax Buy, $12 PT
Thursday, August 11, 2011 - 4:41pm | 96McNicoll, Lewis & Vlak reiterated its Affymax (NASDAQ: AFFY) Buy rating and $12 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "AFFY ended 2Q:11 with $73.6M in cash and equivalents, and $39.7M in short term investments. Based on the 2011...
-
Icagen Stockholders Send Second Letter to Icagen Board to Contest Proposed Price of Acquisition by Pfizer
Thursday, August 11, 2011 - 4:21pm | 229Merlin Nexus and New Leaf Venture Partners (NLV Partners), stockholders in Icagen, Inc. (Nasdaq: ICGN), submitted a second letter to the Icagen Board contesting the company's planned acquisition by Pfizer Inc (NYSE: PFE). According to a July 20, 2011 press announcement, Pfizer plans to purchase the...
-
McNicoll, Lewis & Vlak Maintains Icagen Hold
Thursday, August 11, 2011 - 3:06pm | 113McNicoll, Lewis & Vlak maintained its Icagen (NASDAQ: ICGN) Hold rating in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We maintain our hold rating as ICGN prepares for its acquisition by Pfizer. It should be noted that ICGN's second largest shareholder...
-
Calls Purchased on Neurocrine Biosciences
Thursday, August 11, 2011 - 12:27pm | 106Shares of Neurocrine Biosciences (NASDAQ: NBIX) are higher on the session by 1.61%, currently trading at $5.68. The stock has been moving largely lower over the past six weeks and is currently trading below the 50-day moving average. Options traders are buying calls on the name today. A short...